Assignee
CATALYST BIOSCIENCES INC
US·17 granted patents·4 pending applications·185 citations·filing 1999–2021
Top patents by PatentIndex Score
21 records- 0195US7227009B2MT-SP1 polynucleotides and polypeptidesCATALYST BIOSCIENCES INC·Filed 2005·Granted Jun 5, 2007·35 cites·9 claims
- 0293US7030231B1Membrane type serine protease 1 (MT-SP1) and uses thereofCATALYST BIOSCIENCES INC·Filed 1999·Granted Apr 18, 2006·90 cites·6 claims
- 0391US7939304B2Mutant MT-SP1 proteases with altered substrate specificity or activityCATALYST BIOSCIENCES INC·Filed 2005·Granted May 10, 2011·17 cites·17 claims
- 0489US8383388B2Modified coagulation factor IX polypeptides and use thereof for treatmentCATALYST BIOSCIENCES INC·Filed 2007·Granted Feb 26, 2013·22 cites·65 claims
- 0588US9476037B2Factor VII polypeptides that are modified and uses thereofCATALYST BIOSCIENCES INC·Filed 2013·Granted Oct 25, 2016·8 cites·30 claims
- 0688US9359598B2Mutant MT-SP1 proteases with altered substrate specificity or activityCATALYST BIOSCIENCES INC·Filed 2013·Granted Jun 7, 2016·7 cites·13 claims
- 0783US11203749B2Factor VII polypeptides that are modified and uses thereofCATALYST BIOSCIENCES INC·Filed 2018·Granted Dec 21, 2021·1 cites·6 claims
- 0883US10258582B2Nicotinic receptor non-competitive antagonistsCATALYST BIOSCIENCES INC·Filed 2018·Granted Apr 16, 2019·2 cites·3 claims
- 0982US11266724B2Modified factor VII polypeptides for subcutaneous administration and on-demand treatmentCATALYST BIOSCIENCES INC·Filed 2021·Granted Mar 8, 2022·1 cites·17 claims
- 1081US10160961B2Factor VII polypeptides that are modified and uses thereofCATALYST BIOSCIENCES INC·Filed 2016·Granted Dec 25, 2018·2 cites·26 claims
- 1173US10954501B2Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of useCATALYST BIOSCIENCES INC·Filed 2020·Granted Mar 23, 2021·0 cites·44 claims
- 1272US11401513B2Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of useCATALYST BIOSCIENCES INC·Filed 2020·Granted Aug 2, 2022·0 cites·41 claims
- 1372US10716770B2Nicotinic receptor non-competitive antagonistsCATALYST BIOSCIENCES INC·Filed 2019·Granted Jul 21, 2020·0 cites·5 claims
- 1470US2021230570A1Modified factor ix polypeptides and uses thereofCATALYST BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 1569US10781435B2Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of useCATALYST BIOSCIENCES INC·Filed 2018·Granted Sep 22, 2020·0 cites·38 claims
- 1662US10982203B2Modified factor IX polypeptides and uses thereofCATALYST BIOSCIENCES INC·Filed 2016·Granted Apr 20, 2021·0 cites·42 claims
- 1759US2017071878A1Nicotinic receptor non-competitive antagonistsCATALYST BIOSCIENCES INC·Filed 2016·Application pending·0 cites
- 1857US2021069306A1Modified factor vii polypeptides for subcutaneous administration and on-demand treatmentCATALYST BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 1954US9856467B2Modified factor X polypeptides and uses thereofCATALYST BIOSCIENCES INC·Filed 2014·Granted Jan 2, 2018·0 cites·35 claims
- 2049US2021238260A1Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptidesCATALYST BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 2145US11491212B1Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia BCATALYST BIOSCIENCES INC·Filed 2018·Granted Nov 8, 2022·0 cites·27 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →